Prevention of thyroid associated-ophthalmopathy in children and adults: Current views and management of preventable risk factors

Pediatric Endocrinology Reviews

Volumn 4, Issue 3, 2007, Pages 218-224

  Krassas, Gerasimos E ^a   Perros, Petros ^b  

^a PANAGIA GENERAL HOSPITAL   (Greece)

^b FREEMAN HOSPITAL   (United Kingdom)

Author keywords

Childhood Graves' ophthalmopathy; Graves' ophthalmopathy; Prevention; Smoking

Indexed keywords

ANTITHYROID AGENT; GLUCOCORTICOID; LEVOTHYROXINE; RADIOACTIVE IODINE;

AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE MARKER; EARLY DIAGNOSIS; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; GRAVES DISEASE; HUMAN; PASSIVE SMOKING; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING; SMOKING CESSATION; THYROID DISEASE;

ADULT; CHILD; GRAVES OPHTHALMOPATHY; HUMANS; MORBIDITY; PROGNOSIS; RISK FACTORS; SMOKING; THYROIDECTOMY; TOBACCO SMOKE POLLUTION;

EID: 34247194590     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Marketos SG, Eftychiadis A, Koutras DA. The first recognition of the association between goiter and exophthalmos. J Endocrinol Invest 1983;6:401-403
2. Drury MI. Robert Graves - 150 years ago. Ir J Med Sci 1985;154:470-471
3. Parry C. Collections from the Unpublished Medical Writings. London: Underwood 1825;2:111
4. Graves RJ. Newly observed affection of the thyroid gland in females. In: Major RH, ed. Classic Descriptions of Disease: With Biographical Sketches of the Authors. Springfield, IL: Charles Thomas 1945;280
5. Foley TP Jr. Thyrotoxicosis in childhood. Pediatric Annals 1992;21:43-46, 48-49
6. Saxena KM, Crawford JD, Talbot NB. Childhood thyrotoxicosis: a long-term perspective. Br Med J 1964;2:1153-1158
7. Krassas GE. Treatment of juvenile Graves' disease and its ophthalmic complication: the 'European way'. Eur J Endocrinol 2004;150:407-414
8. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000;21:168-199
9. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001;144:311-318
10. Gorman CA. Temporal relationship between onset of Graves' ophthalmopathy and diagnosis of thyrotoxicosis. Mayo Clin Proc 1983;58:515-519
11. Wiersinga WM, Smit T, van der Gaag R, Koornneef L. Temporal relationship between onset of Graves' ophthalmopathy and onset of thyroidal Graves' disease. J Endocrinol Invest 1988;11:615-619
12. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol (Copenh) 1989;120:473-478
13. Wiersinga WM, Prummel MF. Pathogenesis of Graves' ophthalmopathy-current understanding. J Clin Endocrinol Metab 2001;86:501-503
14. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993;14:747-793
15. Krassas GE, Boboridis K. Recent developments in the medical treatment of thyroid eye disease. Orbit 2006;25:117-122
16. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. Lancet 1990;335:1261-1263
17. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993;269:479-482
18. Krassas GE, Wiersinga WM. Thyroid Eye Disease: Current Concepts and the EUGOGO Perspective. Thyroid International 2005;4:1-21
19. Wiersinga WM, Perros P, Kahaly GJ, Mourits MP, Baldeschi L, Boboridis K, Boschi A, Dickinson AJ, Kendall-Taylor P, Krassas GE, Lane CM, Lazarus JH, Marcocci C, Marino M, Nardi M, Neoh C, Orgiazzi J, Pinchera A, Pitz S, Prummel MF, Sartini MS, Stahl M, von Arx G. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155:387-389
20. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc 1994;92:477-588
21. Krassas GE, Segni M, Wiersinga WM. Childhood Graves' ophthalmopathy: results of a European questionnaire study. Eur J Endocrinol 2005;153:515-521
22. Durairaj VD, Bartley GB, Garrity JA. Clinical features and treatment of Graves ophthalmopathy in pediatric patients. Ophthal Plast Reconstr Surg 2006;22:7-12
23. Krassas GE, Boboridis KG, Wiersinga WM. Re: "clinical features and treatment of graves ophthalmopathy in pediatric patients". Ophthal Plast Reconstr Surg 2006;22:405-406
24. Fletcher RH, Fletcher SW, Wagner EH. Clinical Epidemiology. The Essentials, 2nd edn. Baltimore. Williams & Wilkins 1988;157-171
25. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002;12:855-860
26. Gamblin GT, Harper DG, Galentine P, Buck DR, Chernow B, Eil C. Prevalence of increased intraocular pressure in Graves' disease-evidence of frequent subclinical ophthalmopathy. N Engl J Med 1983;308:420-424
27. th. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 1986;7:651-656
28. Bartalena L, Marcocci C, Pinchera A. Graves' ophthalmopathy: a preventable disease? Eur J Endocrinol 2002;146:457-461
29. Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking? Br Med J (Clin Res Ed) 1987;295:634-635
30. Bartalena L, Bogazzi F, Tanda ML, Manetti L, Dell'Unto E, Martino E. Cigarette smoking and the thyroid. Eur J Endocrinol 1995;133:507-512
31. Bartalena L, Martino E, Marcocci C, Bogazzi F, Panicucci M, Velluzzi F, Loviselli A, Pinchera A. More on smoking habits and Graves' ophthalmopathy. J Endocrinol Invest 1989;12:733-737
32. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996;45:477-481
33. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2004;89:6077-6086
34. Krassas GE, Wiersinga WM. Smoking and autoimmune thyroid disease: the plot thickens Eur J Endocrinol 2006;154:777-780
35. WHO Regional Office for Europe. Tobacco Control Database 2005
36. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998;129:632-635
37. Prummel MF, Wiersinga WM, Mourits MP. Amelioration of eye changes of Graves' ophthalmopathy by achieving euthyroidism. Acta Endocrinol 1989;121(Supp 2):185-189
38. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. Arch Intern 1990;150:1098-1101
39. Karlsson F, Westermark K, Dahlberg PA, Jansson R, Enoksson P. Ophthalmopathy and thyroid stimulation. Lancet 1989;2:691
40. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73-78
41. Marcocci C, Bruno-Bossio G, Manetti L, Tanda ML, Miccoli P, Iacconi P, Bartolomei MP, Nardi M, Pinchera A, Bartalena L. The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study. Clin Endocrinol (Oxf) 1999;51:503-508
42. Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998;338:121-122
43. Pinchera A, Bartalena L, Marcocci C. Therapeutic controversies. Radioiodine may be bad for Graves' ophthalmopathy, but.... J Clin Endocrinol Metab 1995;80:342-345
44. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-1738
45. Gorman CA. Therapeutic controversies. Radioiodine therapy does not aggravate Graves' ophthalmopathy. J Clin Endocrinol Metab 1995;80:340-342
46. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Pinchera A. Relationship between Graves' ophthalmopathy and type of treatment of Graves' hyperthyroidism. Thyroid 1992;2:171-178
47. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321-5323